Translational Research – University of Copenhagen

DanStem > Research > Translational Research

Translational Research

Translational Stem Cell Research and Therapy is focused on the translation of promising basic research results into new strategies and targets for the development of new therapies for hematological cancer and diabetes. The aim is to strengthen these fields towards clinical application.

Top priorities:

  • Development of a safe and efficient therapy for diabetes based on human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs), including development of scalable differentiation protocols for functional insulin-producing beta cells.
  • Establishment of human iPSC-based in vitro models for inherited forms of diabetes.
  • Identification and validation of novel targets for anti-cancer therapy.
  • Strengthening both the short- and long-term research and clinical management of blood cancer.

The programmes are:

Programme for Translational Diabetes Research

Semb Laboratory has the goal to develop large-scale manufacturing protocols of for stem-cell derived allogenicmature beta cells for future clinical needs. ... read more

PanCryos: PanCryos is a prospective spin out company arising from DanStem, aiming to develop a next generation stem cell derived allogenic cell therapy (PanINSULA™) for type 1 diabetes, based on novel IP in the differentiation of stem cells into mature beta cells and in the purification of pancreatic progenitor cells. 

See more informatrion about Stem Cells and Diabetes 


Programme for Translational Hematology (PTH)

Helin Laboratory investigates the mechanisms that regulate cell-fate decisions in stem cells, differentiated cells as well as tumor cells with the aim of gaining new insights into the molecular mechanisms leading to cancer ... read more

Porse Laboratory focuses on the role of transcription factors in normal and malignant hematopoiesis and nonsense-mediated mRNA decay (NMD) in vivo... read more

Wennerberg Laboratory aims to discover novel personalized therapeutic strategies and define and understand the molecular mechanisms driving the cancers, their drug responses and mechanisms of resistance. read more

Grønbæk Laboratory aims to understand and target the progression from clonal cytopenia of undetermined significance (CCUS) to myelodysplastic syndrome (MDS) as well as the molecular aberrations underlying mantle cell lymphoma (MCL).

Theilgaard-Mønch Laboratory major focus is to characterize and target cancer stem cells (CSCs), as well a to improve prognostification in patients with Acute Myeloid Leukemia (AML)… read more

Kyoung-Jae Won , group for Bioinformatics.  (TBA)